<DOC>
	<DOC>NCT00869388</DOC>
	<brief_summary>This study will evaluate toxicity associated with escalating doses of rBBX-01 given bi-weekly to patients with solid tumors.</brief_summary>
	<brief_title>A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed metastatic or unresectable, resistant solid tumor. Gynecologic tumors preferred. 18 years and above GOG performance status greater than or equal to 2 Life expectancy greater than 6 months Acceptable organ and marrow function Willingness to agree to use adequate contraception prior to study entry and for the duration of study participation Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or have not recovered from adverse events due to agents administered more than 4 weeks earlier Not receiving any other investigational agents Known brain metastasis Uncontrolled intercurrent illness including, but not limited to ongoing ore active infection, symptomatic congestive heart failure, unstable angina pectoris,cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements Pregnancy Immunosuppression including subjects with known HIV infection on immunosuppressive drugs or having an autoimmune disorder Penicillin allergy Symptomatic prostate hypertrophy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>malignant</keyword>
	<keyword>resistant</keyword>
	<keyword>solid tumor</keyword>
</DOC>